Back to top

Analyst Blog

Zacks Equity Research

Is Mylan N.V. (MYL) a Great Stock for Value Investors?

MYL

Trades from $3

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Mylan N.V. (MYL - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Mylan N.V. has a trailing twelve months PE ratio of 8.66, as you can see in the chart below:

This level is significantly favorable with the market at large, as the PE for the S&P 500 compares in at about 20.48. If we focus on the stock’s long-term PE trend, the current level puts Mylan N.V.’s current PE ratio below its midpoint (which is 11.62) over the past five years. Moreover, the current level is below the highs for this stock, suggesting that the stock is undervalued compared to its historical levels.

Further, the stock’s PE also compares favorably with the Zacks classified Medical sector’s trailing twelve months PE ratio, which stands at 18.89. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Mylan N.V. has a forward PE ratio (price relative to this year’s earnings) of just 7.92, so it is fair to say that a slightly more value-oriented path may be ahead for Mylan N.V. stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Mylan N.V. has a P/S ratio of about 2.04. This is somewhat lower than the S&P 500 average, which comes in at 3.10 right now. Also, as we can see in the chart below, this is much below the highs for this stock in particular over the past few years.

If anything, this suggests some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Mylan N.V. currently has a Zacks Value Style Score of ‘A’, putting it into the top 20% of all stocks we cover from this look. This makes MYL a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the PEG ratio for Mylan N.V. is just 1.06, a level that is slightly lower than the industry average of 1.10. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, MYL is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Mylan N.V. might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of ‘B’ and a Momentum score of ‘D’. This gives MLV a Zacks VGM score—or its overarching fundamental grade—of ‘A’. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen one estimate go lower in the past thirty days, compared to none higher, while the full year estimate has seen three upward and one downward revisions in the same time period.

This has had a mixed impact on the consensus estimate, as the current quarter consensus estimate has declined 12.6% in the past one month, while the full year estimate has inched up 0.4%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Mylan N.V. Price and Consensus

 

Mylan N.V. Price and Consensus | Mylan N.V. Quote

This mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.

Bottom Line

Mylan N.V. is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However with a sluggish industry rank (bottom 32% out of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the Zacks classified Medical-Generic Drugs sector has significantly underperformed the broader market, as you can see below:

So, value investors might want to wait for analyst sentiment and broader factors to turn favorable in this name first, but once that happens, this stock could be a compelling pick.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Mylan N.V. (MYL) - free report >>